Partnering with Eurofins Discovery grants you priority access to one of the industry’s broadest portfolios of GPCR and kinase products and services, as well as to validated in vitro pharmacology (LeadHunter™), ADMET, and chemistry services for integrated drug discovery solutions targeting the most promising target classes. That advantage can matter when working in target-based in vitro screening that is central to identifying hits from high-throughput screens, optimizing leads, and accelerating preclinical candidates into the clinic. Successfully navigating the development process requires reliable, ready-to-use assays that have been validated at each step, so you can generate trustworthy data and make well-informed, timely choices about moving ahead with the most promising compounds.
The Eurofins Discovery advantage: Partnering with our expert teams delivers the organizational stability of a respected global leader with an effective international network working together to provide quick turn-around times. We offer access to the largest portfolio of ready-to-use biochemical and functional assays, covering a wide range of drug targets, including GPCRs, kinases, ion channels and epigenetics, and more.
Our best-in-class assays are developed in-house using innovative technologies, including label-free detection methods, delivering reproducible, rapid, and cost-effective results that you can’t get anywhere else. Whether you’re developing a high-throughput screening workflow, advancing your hits to leads, optimizing for potency and/or selectivity, or vetting preclinical candidates, we are here to provide personalized guidance, technical expertise, and robust data so you can make enlightened decisions throughout the drug development process. What discoveries await you with the Eurofins Discovery world of resources?
Advance Your Drug Discovery with our Unparalleled Portfolio of Off-the-Shelf Assays Against Challenging Targets, LeadHunter
Key Areas
GPCRs
G-protein Coupled Receptors (GPCRs) play an important role in disease pathogenesis and constitute the largest family of transmembrane proteins in the human genome, making them one of the most attractive therapeutic target classes.
Kinases
Complete your custom protein production, assay development, screening, and kinase selectivity profiling needs with confidence.
SH2scan
Evaluate SH2 domain mediated protein-protein interactions (PPIs) and phosphotyrosine-based signaling using LeadHunter™ Src Homology 2 (SH2) domain binding assays, SH2scan, targeting kinases, Signal Transducer and Activation of Transcription (STAT) and more, to support drug discovery research for diverse disease indications including cancer, inflammation, and autoimmune diseases.
Ion Channels
Investigate ion channel targets and/or assess drug safety profiles early in the drug discovery process.
Nuclear Receptors
Develop a complete profile of your compounds against NHRs using both binding and functional assays.
Epigenetics
Better Understand your epigenetics drug discovery programs.
Proteases
Screen and profile against a broad panel of protease targets to further develop your protease drug discovery programs.
Phosphatases
Screen your focused chemical libraries or profile your lead compounds for their inhibitory effects on phosphatases.
Pathway Profiling
LeadHunter® Discovery Services provides you access to a comprehensive collection of cell-based pathway indicator assays designed to detect activation or inhibition of complex signal transduction pathways in response to compound treatment.
BCL2 Profiling
Biochemical Ligand Binding Assays for BCL2, BCLXL, BCLW, BCL2A1 and MCL1
Targeted Protein Degradation
The generic approach to target disease-causing proteins is through small molecules that bind to and inhibit the enzymatic activity of the protein.
PPIase
Discover inhibitors of Peptidyl Prolyl Isomerases. Unique panel of assays covering selected Cyclophilins, Pin1 and FBKPs
Transporters
Transporters are membrane proteins that control the influx and efflux of essential nutrients, ions, neurotransmitters, cellular waste, environmental toxins, and other xenobiotics such as drugs.
Cytochrome P450
Better understand the metabolic activity of your compounds to evaluate potential Drug-Drug Interactions (DDI).
Cytokine Profiling
Current cell-based methodologies to characterize biologics targeting interleukins include proliferation or cytokine release assays which require the use of primary cells.
PDEs
Determine the inhibitory effects and selectivity of compounds on the PDE superfamily with confidence.
Checkpoint Receptors
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers.
Mitochondrial Assays
Discover inhibitors of Mitochondrial Permeability transition pore.
Bromoscan-Competitive Ligand Binding Assay
Eurofins Discovery offers a suite of assays for epigenetic targets to enable identification and classification of inhibitors based on potency, selectivity and in vitro efficacy.
Gene Expression Assays
Compound screening in cell-based gene expression assays utilizing Fluidigm microfluidics-based qPCR technology
Phagocytosis and Efferocytosis Assays
In vitro models of pro-inflammatory phagocytosis and anti-inflammatory efferocytosis are available for compound screening by High-content Imaging.
Helicases
Pioneering advances in the field of helicases, Eurofins Discovery's highly skilled scientists are developing solutions from HTS to safety de-risking.
Features
FAQs
Related Solutions
Features
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
